Date: 29 November 2018
A patient at East Lancashire Hospitals NHS Trust (ELHT) is the first to take part in the ACE research study.
The research collects cognitive assessment data in patients with metastatic prostate cancer who have started abiraterone acetate and prednisolone (AAP) or enzalutamide (ENZ) as a line of therapy.
Both AAP and ENZ have been shown to extend survival and improve health-related quality of life for this group of patients, but information about their early impact on aspects of cognitive impairment, fatigue and depression is limited.
ELHT has been supported by NIHR Clinical Research Network, Greater Manchester, and the study is on the NIHR CRN Portfolio.
L-R: Maricica Zabrautanu, Team Lead, Sarah Keith, Research Nurse, Janet Ryan-Smith, Research Support Officer, Jeanette Smalley, Senior Research Support Officer
Alongside their usual hospital follow-up, participants in the ACE study will complete a series of cognitive assessments and questionnaires over a 12-month period.
Led locally at ELHT by Principal Investigator, Dr Omi Parikh, and supported by the Trust’s Cancer Research Team, the study opened at ELHT on 9 November 2018 and will continue for two years.
Dr Parikh thanked patients for taking part in the research and said: “I’m really pleased to be offering trials which evaluate quality of life to our patients and I’m very grateful to the patients for taking part.
"I’d also like to thank the research team for facilitating this quite complex trial and overcoming multiple barriers to have been able to recruit our first patients in a matter of weeks of opening the trial."
The research is led by Chief Investigator, Professor Amit Bahl and sponsored by University Hospitals Bristol NHS Foundation Trust. The study is funded by a grant from Janssen-Cilag Limited.
You may also be interested in